Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients
Language English Country Switzerland Media print
Document type Comparative Study, Journal Article
PubMed
1618007
DOI
10.1159/000238944
Knihovny.cz E-resources
- MeSH
- Agranulocytosis complications MeSH
- Amikacin administration & dosage therapeutic use MeSH
- Bacterial Infections drug therapy MeSH
- Ceftriaxone administration & dosage therapeutic use MeSH
- Adult MeSH
- Fever drug therapy MeSH
- Drug Therapy, Combination therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasms complications MeSH
- Netilmicin administration & dosage therapeutic use MeSH
- Retrospective Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
- Names of Substances
- Amikacin MeSH
- Ceftriaxone MeSH
- Netilmicin MeSH
For the treatment of febrile episodes in granulocytopenic cancer patients, a combination of bactericidal and intravenously administered broad spectrum agents is recommended. An aminoglycoside plus a beta-lactame (piperacillin, azlocillin or IIIrd generation cephalosporins) are the drugs of first choice in an empiric approach. Because of frequent parenteral interventions (e.g. catheters, cannulations) in thrombopenic patients with multifactorial immunosuppression, we consider the application of once daily drugs, such as ceftriaxone, netilmicin or amikacin. For single dose treatment (1st day two applications), we used ceftriaxone in combination with netilmicin or amikacin as the first approach and retrospectively evaluated 47 patients for efficacy and safety.
References provided by Crossref.org
